{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:45:45Z","timestamp":1772196345164,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.vaccine.2010.06.065","type":"journal-article","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T09:20:54Z","timestamp":1277889654000},"page":"5837-5844","source":"Crossref","is-referenced-by-count":85,"title":["Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6\u201335 months"],"prefix":"10.1016","volume":"28","author":[{"given":"Alfonso","family":"Carmona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Ome\u00f1aca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Tejedor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejaswini","family":"Vaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Dieussaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ar\u00edstegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.06.065_bib1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.06.065_bib2","doi-asserted-by":"crossref","first-page":"e4384","DOI":"10.1371\/journal.pone.0004384","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2010.06.065_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1086\/590913","article-title":"An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults","volume":"198","author":"Levie","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.06.065_bib4","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1073\/pnas.0601266103","article-title":"Mitigation strategies for pandemic influenza in the United States","volume":"103","author":"Germann","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2010.06.065_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","article-title":"Strategies for mitigating an influenza pandemic","volume":"442","author":"Ferguson","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2010.06.065_bib6","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1016\/j.vaccine.2007.05.033","article-title":"Pre- or post-pandemic influenza vaccine? Editorial","volume":"25","author":"Osterhaus","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.065_bib7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1473-3099(08)70232-9","article-title":"Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans","volume":"8","author":"Jennings","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2010.06.065_bib8","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa0907413","article-title":"Response to a monovalent 2009 influenza A (H1N1) vaccine","volume":"361","author":"Greenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.06.065_bib9","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.06.065_bib10","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2009.12.014","article-title":"Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial","volume":"28","author":"Roman","year":"2010","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2010.06.065_bib11","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","article-title":"Emergence of a novel swine-origin influenza A (H1N1) virus in humans","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.06.065_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.1176062","article-title":"Pandemic potential of a strain of influenza A (H1N1): early findings","volume":"324","author":"Fraser","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2010.06.065_bib13","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2009.1536","article-title":"Critically ill patients with 2009 influenza A(H1N1) in Mexico","volume":"302","author":"Dom\u00ednguez-Cherit","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.06.065_bib14","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1001\/jama.2009.1496","article-title":"Critically ill patients with 2009 influenza A(H1N1) infection in Canada","volume":"302","author":"Kumar","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.06.065_bib15","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(09)61638-X","article-title":"Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis","volume":"374","author":"Echevarr\u00eda-Zuno","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.06.065_bib16","doi-asserted-by":"crossref","first-page":"b5213","DOI":"10.1136\/bmj.b5213","article-title":"Mortality from pandemic A\/H1N1 2009 influenza in England: public health surveillance study","volume":"339","author":"Donaldson","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2010.06.065_bib17","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1056\/NEJMoa051721","article-title":"Influenza-associated deaths among children in the United States, 2003\u20132004","volume":"353","author":"Bhat","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.06.065_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/01.inf.0000220208.59965.95","article-title":"Influenza-related hospitalizations in children younger than three years of age","volume":"25","author":"Rojo","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2010.06.065_bib19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1542\/peds.2006-2679","article-title":"Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza","volume":"119","author":"Coffin","year":"2007","journal-title":"Pediatrics"},{"issue":"RR-10","key":"10.1016\/j.vaccine.2010.06.065_bib20","first-page":"1","article-title":"Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"58","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2010.06.065_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/adc.2006.101477","article-title":"Children, avian influenza H5N1 and preparing for the next pandemic","volume":"93","author":"Nicoll","year":"2008","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2010.06.065_bib22","unstructured":"American Academy of Pediatrics. Pandemic influenza: warning, children at-risk; October 2007 (accessed May 10th, 2010 at http:\/\/www.aap.org\/new\/KidsPandemicFlufnl.pdf)."},{"key":"10.1016\/j.vaccine.2010.06.065_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/aje\/kwp237","article-title":"Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States","volume":"170","author":"Basta","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2010.06.065_bib24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2010.250","article-title":"Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial","volume":"303","author":"Loeb","year":"2010","journal-title":"JAMA"},{"issue":"RR-08","key":"10.1016\/j.vaccine.2010.06.065_bib25","first-page":"1","article-title":"Prevention control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"58","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2010.06.065_bib26","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1056\/NEJMoa0908535","article-title":"A novel influenza A (H1N1) vaccine in various age groups","volume":"361","author":"Zhu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.06.065_bib27","unstructured":"NIH Bulletin. Updated results: in youngest children, a second dose of 2009 H1N1 influenza vaccine elicits robust immune response (accessed May 10th, 2010 at http:\/\/www3.niaid.nih.gov\/news\/newsreleases\/2009\/interimpedsdata.htm)"},{"key":"10.1016\/j.vaccine.2010.06.065_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(09)62026-2","article-title":"Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials","volume":"375","author":"Plennevaux","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.06.065_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.1911","article-title":"Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children","volume":"303","author":"Nolan","year":"2010","journal-title":"JAMA"},{"issue":"45","key":"10.1016\/j.vaccine.2010.06.065_bib30","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2009.01.040","article-title":"Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.065_bib31","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"R\u00fcmke","year":"2008","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2010.06.065_bib32","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1016\/j.vaccine.2009.07.102","article-title":"Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults","volume":"27","author":"Chu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.065_bib33","unstructured":"World Health Organization. Availability of a candidate reassortant vaccine virus for the novel Influenza A (H1N1) vaccine development X-179A (accessed November 19th, 2009, at http:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/candidates_X-179a\/en\/)."},{"key":"10.1016\/j.vaccine.2010.06.065_bib34","unstructured":"European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA\/CHMP\/VWP\/263499\/2006). European Agency for the Evaluation of Medicinal Products, January 24; 2007."},{"key":"10.1016\/j.vaccine.2010.06.065_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00044011-200222110-00004","article-title":"Ten years of experience with the trivalent split-influenza vaccine, Fluarix\u2122","volume":"22","author":"Hehme","year":"2002","journal-title":"Clin Drug Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2010.06.065_bib36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2010.06.065_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.06.065_bib38","unstructured":"FDA Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007 (accessed May 10th, 2010, at http:\/\/www.fda.gov\/cber\/gdlns\/panfluvac.htm)."},{"key":"10.1016\/j.vaccine.2010.06.065_bib39","unstructured":"Study No 100351-056. A phase III double-blind, randomized, multicentric, comparative vaccination study of the immunogenicity and reactogenicity of a thiomersal free formulation of Influsplit SSW\u00ae 2003\/2004 versus the standard formulation of Influsplit SSW\u00ae 2003\/2004 in children aged from 6 months to <6 years (accessed May 10th, 2010, at http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/3229.pdf)."},{"key":"10.1016\/j.vaccine.2010.06.065_bib40","unstructured":"Study No 104858 (Fluarix-US-005). A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix\u00ae (GSK Biologicals) compared with Fluzone\u00ae (Aventis Pasteur\/Sanofi) administered intramuscularly in children (6 months and older) (accessed May 10th, 2010, at http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/20022.pdf)."},{"key":"10.1016\/j.vaccine.2010.06.065_bib41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/adc.83.6.488","article-title":"Safety and immunogenicity of a paediatric presentation of an influenza vaccine","volume":"83","author":"Gonzalez","year":"2000","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2010.06.065_bib42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/01.inf.0000180978.66362.d9","article-title":"Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003\u20132002","volume":"24","author":"Mitchell","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2010.06.065_bib43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/INF.0b013e31819d6394","article-title":"Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2010.06.065_bib44","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1016\/j.vaccine.2009.08.032","article-title":"Evaluation of the safety, reactogenicity and immunogenicity of FluBlok\u00ae trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6\u201359 months","volume":"27","author":"King","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.065_bib45","doi-asserted-by":"crossref","first-page":"b4313","DOI":"10.1136\/bmj.b4313","article-title":"H1N1 pandemic flu found to cause viral pneumonia in severe cases, says WHO","volume":"339","author":"Zarocostas","year":"2009","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.vaccine.2010.06.065_bib46","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2009.1535","article-title":"Extracorporeal membrane oxygenation for 2009 Influenza A(H1N1) acute respiratory distress syndrome","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.06.065_bib47","series-title":"Influenza Vaccines for the World (IVW)","article-title":"Single-Dose primary vaccination with AS03A-adjuvanted prepandemic H5N1 influenza vaccine is sufficient to induce strong, rapid and broad immune response to booster vaccination after 12 Months","author":"Schwarz","year":"2009"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.065_bib48","doi-asserted-by":"crossref","first-page":"e35-e46","DOI":"10.1097\/INF.0b013e3181daf921","article-title":"Immunogenicity and safety of H5N1 A\/Vietnam\/1194\/2004 (clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: a Phase II, randomized, open, controlled study","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2010.06.065_bib49","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1542\/peds.2004-2373","article-title":"A Comparison of 2 influenza vaccine schedules in 6- to 23-month-old children","volume":"115","author":"Englund","year":"2005","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1000887X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1000887X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T10:50:01Z","timestamp":1635591001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1000887X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":49,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0264410X1000887X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}